Common Contracts
1 similar Toll Manufacturing Agreement contracts
Toll Manufacturing Agreement for the Bulk Drug Substance of Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal AntibodyToll Manufacturing Agreement • July 30th, 2008
July 31, 2008 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku, Tokyo; President Osamu Nagayama (hereafter, “Chugai”)] announced today that on July 30 (Eastern Daylight Time), the company executed a toll manufacturing and supply agreement for the bulk drug substance of Actemra®, a humanized anti-human IL-6 receptor monoclonal antibody, with Genentech, Inc. [Head Office: California, USA; Chairman & CEO Arthur D. Levinson (hereafter, “Genentech”)], which is majority-owned by F. Hoffmann-La Roche Ltd. [Head Office: Basel, Switzerland; CEO: Severin Schwan (hereafter “Roche”)]. Genentech, as a toll manufacturer for Chugai, will manufacture Actemra® bulk drug substance following the completion of a manufacturing licensing transfer from Chugai. The Utsunomiya Plant of Chugai Pharma Manufacturing Co., Ltd., a wholly-owned subsidiary of Chugai, will also continue producing Actemra® bulk drug substance to its final formulation.
